Patents Issued in July 1, 2014
  • Patent number: 8765923
    Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: July 1, 2014
    Assignee: Heliae Development, LLC
    Inventor: Aniket Kale
  • Patent number: 8765924
    Abstract: This invention relates to novel protein conjugates, in particular, to novel pegylated proteins, and their methods of making and use. One aspect of the present invention relates to pegylated-erythropoietin having greater clinical efficacy and stability during shipment and storage than current erythropoietin formulations.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: July 1, 2014
    Assignee: Prolong Pharmaceuticals, Inc.
    Inventors: Abraham Abuchowski, Lihsyng Stanford Lee
  • Patent number: 8765925
    Abstract: A method for preparation of Timosaponin BII, which uses Chinese traditional medicine Rhizoma Anemarrhenae or fresh rhizoma or fibrous root of Anemarrhena asphodeloides Bge. as raw material, and comprises isolation of Timosaponin BII by one or more processes selected from solvent extraction, resin adsorption, polyamide chromatography, reversed phase column chromatography, Sephadex LH-20 column chromatography, etc, combining with conventional drying method such as reduced pressure drying, freeze drying, spray drying, and so on. Timosaponin BII obtained by the present method is of over 90% purity, and the method is simple, practicable and suitable for industrial production.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: July 1, 2014
    Assignee: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA
    Inventors: Baiping Ma, Hao Chen, Chengqi Xiong, Liping Kang, Jie Zhang
  • Patent number: 8765926
    Abstract: The present invention pertains to a supramolecular structure based on i-motif tetramers of Cm—X—Cn oligonucleotides, wherein m and n are integers comprised between 2 and 9, and X is a linker such as A, T, G, a modified deoxynucleotide or a diol spacer. These supramolecular structures can be dissociated, when necessary, by a mere pH change. The present invention also relates to methods for obtaining such a supramolecular structure.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 1, 2014
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Denis Pompon, Jean-Louis Leroy, Aude Laisne
  • Patent number: 8765927
    Abstract: Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 and methods of use.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: July 1, 2014
    Inventor: James Ryan
  • Patent number: 8765928
    Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: July 1, 2014
    Assignee: Ryogen LLC
    Inventor: James Ryan
  • Patent number: 8765929
    Abstract: The objective of the present invention is to provide a transformation method that is applicable to a wide variety of species of algae with high efficiency. The promoter of the present invention is characterized in containing a polynucleotide constituting a non-coding region located upstream from a gene encoding a replication-associated protein of a CdebDNA virus or the like.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: July 1, 2014
    Assignee: Kochi University
    Inventors: Masao Adachi, Keizo Nagasaki, Yuji Tomaru
  • Patent number: 8765930
    Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAI. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: July 1, 2014
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
    Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
  • Patent number: 8765931
    Abstract: The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at 5 least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: July 1, 2014
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Evgenia Alpert, Igor Mett, Amir Bar-Ilan, Igor Spivak, Hagar Kalinski, Netanja Slager, James D. Thompson
  • Patent number: 8765932
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 1, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Patent number: 8765933
    Abstract: A process of stereoselectively synthesizing ?-nucleoside, e.g., 2?-deoxy-2,2?-difluorocytidine, is described. The process includes reacting a tetrahydrofuran compound of the following formula: in which wherein R1, R2, R3, R4, and L as defined in the specification, with a nucleobase derivative in the presence of an oxidizing agent.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: July 1, 2014
    Assignee: PharmaEssentia Corp.
    Inventors: Chungsun Chien, Pin-Shu Chien, Chan-Kou Hwang
  • Patent number: 8765934
    Abstract: A method for conjugating a nucleic acid with a molecule is provided. The method includes steps of (a) reacting the nucleic acid having a 5?-monophosphate with an activating agent in a first buffer to form a solution; (b) mixing an alcohol with the solution formed in the step (a) to obtain an intermediate; and (c) dissolving the intermediate in a second buffer containing an ethylenediaminetetraacetic acid (EDTA) and adding a nucleophile thereinto to react the intermediate with the nucleophile.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: July 1, 2014
    Assignee: Kaohsiung Medical University
    Inventors: Tzu-Pin Wang, Yi-Jhang Ciou
  • Patent number: 8765935
    Abstract: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: July 1, 2014
    Assignee: Regents of the University of Minnesota
    Inventor: Carston R. Wagner
  • Patent number: 8765936
    Abstract: An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: July 1, 2014
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
  • Patent number: 8765937
    Abstract: A process for the ultrapurification of alginates is provided. In particular, the process may be used for microencapsulation in human cell transplants.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: July 1, 2014
    Assignee: GH Care, Inc.
    Inventors: Giuseppe Pietro Pio Basta, Riccardo Calafiore
  • Patent number: 8765938
    Abstract: The object is to produce a polysaccharide and/or a monosaccharide efficiently by hydrolyzing a different polysaccharide efficiently. The hydrolysis of a polysaccharide is an important means for producing a monosaccharide that can be used as a starting material for the production of ethanol, the solubilization of a water-insoluble polysaccharide, and the production of a useful water-soluble low-polymeric saccharide or the like. For achieving the object, a polysaccharide to be hydrolyzed is reacted with water in the presence of a carbonaceous material having sulfonic acid group therein to cause the hydrolysis of the polysaccharide to be hydrolyzed, thereby producing a other polysaccharide and/or a monosaccharide.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: July 1, 2014
    Assignees: Tokyo Institute of Technology, Nippon Oil Corporation
    Inventors: Michikazu Hara, Shinichiro Yanagawa, Akira Matsuo, Hidesato Kondo
  • Patent number: 8765939
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: July 1, 2014
    Assignees: AstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Nicholas J. Bennett, Thomas McInally, Tobias Mochel, Stephen Thom, Anna-Karin Tidén
  • Patent number: 8765940
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphob
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: July 1, 2014
    Assignee: Amgen Inc.
    Inventors: Matthew Brown, Yi Chen, Timothy David Cushing, Felix Gonzalez Lopez De Turiso, Xiao He, Todd J. Kohn, Julia Winslow Lohman, Vatee Pattaropong, Jennifer Seganish, Youngsook Shin, Jillian L. Simard
  • Patent number: 8765941
    Abstract: Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian influenza, and the hepatitis C have become social menaces. Therefore, the development of a novel antiviral agent that can cope with a virus resistant to an existing drug or a new virus and has a wide range of applications has been demanded. The present invention provides a novel anti-RNA viral agent and a method for use thereof. The present invention further provides an anti-RNA viral agent that is also effective against a new virus or a drug-resistant virus, and a method for use thereof.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: July 1, 2014
    Assignee: Kino Pharma, Inc.
    Inventors: Hiroshi Onogi, Masatoshi Hagiwara, Masaaki Suzuki, Hiroko Koyama, Takamitsu Hosoya, Toshiyuki Hiramatsu
  • Patent number: 8765942
    Abstract: Process for preparing diaminophenothiazinium type compounds having a step for purification of derivatives (II). The diaminophenothiazinium type compounds having the following formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 may be chosen, independently of the others, from the group constituted of: a hydrogen atom, saturated or unsaturated, linear or branched C1-C6 alkyl groups, or C3-C6 cycloalkyl groups, optionally substituted with one or more functions chosen from a halogen atom, and a C1-C6 alkoxy, C1-C6 alkoxycarbonyl or —CONH2 function, aryl groups optionally substituted with one or more functions chosen from: a C1-C4 alkyl, a halogen atom, and a C1-C6 alkoxy, C1-C6 alkyloxycarbonyl or —CONH2 function, in addition, each of R5, R6, R7, R8, R9 and R10 may be chosen, independently of the others, from the halogen atoms: F, Cl, Br and I, and X? represents an organic or inorganic anion.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: July 1, 2014
    Assignee: Provence Technologies
    Inventors: Michel Feraud, Babak Sayah
  • Patent number: 8765943
    Abstract: A 1,2,4-triazine of formula (I): and its process of manufacture and use.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: July 1, 2014
    Assignees: Compagnie Generale des Etablissements Michelin, Michelin Recherche et Technique S.A.
    Inventors: Nicolas Seeboth, Sergey Ivanov, Sergey Molkov
  • Patent number: 8765944
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: July 1, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric Mull, Qian Zhao, Tao Wang, Zhongxing Zhang, Paul Michael Scola
  • Patent number: 8765945
    Abstract: Provided herein are processes for synthesizing dihydropyridophthalazinone derivatives, such as for example, 5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one and its stereoisomers, which are potent poly(ADP-ribose)polymerase (PARP) inhibitors as well as novel synthetic intermediate compounds.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: July 1, 2014
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Bing Wang, Daniel Chu, Yongbo Liu, Quan Jiang, Lei Lu
  • Patent number: 8765946
    Abstract: A method of preparing a compound of formula (I), A method for treating cancer or inhibiting growth of cancer cells including administering to a patient mammal in need thereof a pharmaceutical preparation including the compound. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal including administering to a mammal a pharmaceutical preparation including the compound.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: July 1, 2014
    Inventor: Hesheng Zhang
  • Patent number: 8765947
    Abstract: A preparation method of rosuvastatin calcium (Formula 1), which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Such preparation method is suitable for industrial production. Furthermore, the intermediate crystallines used in the preparation method are provided.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 1, 2014
    Assignee: Changzhou Pharmaceutical Factory
    Inventors: Benshun Chen, Bing Wang, Xiaofeng Jin, Lin Zou
  • Patent number: 8765948
    Abstract: The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: July 1, 2014
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Donald J. Gallagher, Laszlo R. Treiber, Robert Michael Hughes, Onorato Campopiano, Peng Wang, Yuxin Zhao, Michael Allen Ouellette, Donald Nicholas Hettinger, Helen Chou
  • Patent number: 8765949
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: July 1, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Patent number: 8765950
    Abstract: The present disclosure provides isotopically substituted compounds of the formula (II): wherein T, U, V, W, X, Y, Z, R0, R3, R4, R5 and R6 are as defined in the detailed description. The method for detection and quantification using the same is also disclosed.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: July 1, 2014
    Assignee: Purdue Research Foundation
    Inventors: Vincent Jo Davisson, Shirshendu K. Deb, Giselle Marcelline Knudsen-Mooney, Meiguo Xin
  • Patent number: 8765951
    Abstract: This invention provides novel compositions comprising substituted polyamines as acid gas scrubbing solutions and methods of using the compositions in an industrial system. The invention relates to the use of such polyamine compounds in industrial processes to remove acidic contaminants from natural and industrial fluid streams, such as natural gas, combustion gas, natural gas, synthesis gas, biogas, and other industrial fluid streams. The compositions and methods of the invention are useful for removal, absorption, or sequestration of acidic contaminants and sulfide contaminants including CO2, H2S, RSH, CS2, COS, and SO.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: July 1, 2014
    Assignee: Nalco Company
    Inventors: Alan M. Blair, Keith N. Garside, William J. Andrews, Kailas B. Sawant
  • Patent number: 8765952
    Abstract: The present invention provides a metal complex containing a cation represented by [(MII)2(MI)2(LC)2(LB)4]2+ [in the aforementioned formula, MII is PtII or PdII, MI is H+, AuI, AgI, CuI, HgI, TlI or PbI, and LC and LB are ligands]. The metal complex of the present invention is useful as a light emitting material of an organic EL device.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: July 1, 2014
    Assignee: Nagasaki University
    Inventors: Keisuke Umakoshi, Ami Higashitani, Kazutoyo Kimura, Shoji Ishizaka, Noboru Kitamura
  • Patent number: 8765953
    Abstract: The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of MMP inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP inhibitors for the treatment of pain and other diseases such as cancer. Additionally, the present invention relates to methods for treating pain in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: July 1, 2014
    Assignee: Aquilus Pharmaceuticals, Inc.
    Inventor: Irving Sucholeiki
  • Patent number: 8765954
    Abstract: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: July 1, 2014
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Daniel C. Adelman, Marc J. Evanchik, Anantha Sudhakar, Jeffrey William Jacobs, Jeffrey A. Silverman
  • Patent number: 8765955
    Abstract: One aspect of the present invention relates to asymmetric catalytic nitroaldol (Henry) reactions with ketones as the electrophilic component. In one embodiment, the present invention relates to asymmetric nitroaldol reactions with ?-keto esters catalyzed by a new C6?-OH cinchona alkaloid catalyst. In certain embodiments, this reaction is operationally simple and affords high enantioselectivity as well as good to excellent yield for an exceptionally broad range of ?-keto esters.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: July 1, 2014
    Assignee: Brandeis University
    Inventors: Li Deng, Hongming Li
  • Patent number: 8765956
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: July 1, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Patent number: 8765957
    Abstract: The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: July 1, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: John DeMattei, Adam R. Looker, Bobbianna Neubert-Langille, Martin Trudeau, Stefanie Roeper, Michael P. Ryan, Dahrika Milfred Yap Guerette, Brian R. Krueger, Peter D. J. Grootenhuis, Fredrick F. Van Goor, Martyn C. Botfield, Gregor Zlokarnik
  • Patent number: 8765959
    Abstract: Piperidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: July 1, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerald Juergen Roth, Martin Fleck, Bernd Nosse, Thorsten Lehmann-Lintz
  • Patent number: 8765960
    Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 1, 2014
    Assignee: Eli Lilly and Company
    Inventors: Jon Kevin Reel, Warren Jaye Porter
  • Patent number: 8765961
    Abstract: A compound represented by general formula (I) below, or a pharmacologically acceptable salt thereof: wherein X represents sulfonic acid group; R1 and R2 represent substituents; R3 to R6 represent optionally substituted alkyl groups; R7 and R8 represent an optionally substituted alkyl groups; L1 to L3 represent optionally substituted methine groups, with at least one of L1 to L3 being a methine group having a substituent with the bulkiness of an ethyl group or greater; r represents an integer of from 0 to 3, and when r is 2 or more, the plural L2 and the plural L3 may be the same or different, respectively; each of m and n independently represents an integer of 0 to 3; and at least one of the substituents is sulfonic acid group or a group comprising sulfonic acid group, which is useful as an imaging component in a near infrared fluorescence imaging agent.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: July 1, 2014
    Assignee: FUJIFILM Corporation
    Inventor: Hiroshi Koori
  • Patent number: 8765962
    Abstract: The present invention relates to an efficient process for preparing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of the synthesis of Etoricoxib. Water is employed as reaction medium.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: July 1, 2014
    Assignee: F.I.S.—Fabrica Italiana Sintetici S.p.A.
    Inventors: Paolo Stabile, Marco Galvagni
  • Patent number: 8765963
    Abstract: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: July 1, 2014
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu, Amal Ting
  • Patent number: 8765964
    Abstract: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: July 1, 2014
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Patent number: 8765965
    Abstract: The compounds are intermediates in the preparation of therapeutic agents useful in the treatment of viral infections, particularly HIV infection. The compounds are 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid of the formula P-6 and/or methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate of the formula P-7.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: July 1, 2014
    Assignees: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. Johns, Jason G. Weatherhead, Toshikazu Hakogi, Yasunori Aoyama
  • Patent number: 8765966
    Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: July 1, 2014
    Assignee: Idenix Pharmaceuticals, Inc.
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Florence Marie-Emilie Bonnaterre, Dominique Surleraux
  • Patent number: 8765967
    Abstract: The invention provides a process for producing microcapsules with UV filter activity, wherein at least one type of crosslinkable chromophore with UV-A and/or UV-B and/or UV-C filter activity and optionally at least one type of crosslinkable monomer which does not have UV-A and/or UV-B and/or UV-C filter activity are subjected to a crosslinking reaction in the absence of non-crosslinkable chromophores with UV-A and/or UV-B and/or UV-C filter activity and microcapsules obtainable by this process.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: July 1, 2014
    Assignee: DSM IP Assets B.V.
    Inventor: Katja Berg-Schultz
  • Patent number: 8765968
    Abstract: A polymer comprises a polymeric chain represented by formula (I) or (II). In formula (I), a, b, c, d, and n are integers, a from 0 to 3, b from 1 to 5, c from 1 to 3, d from 1 to 5, and n from 2 to 5000; R1 and R2 are side chains; R3 and R4 are each independently H or a side chain; and when a is 0, R3 and R4 are side chains. In formula (II), a, b, c, d, e, and n are integers, a from 1 to 3, b and c being independently 0 or 1, d and e being independently 1 or 2, and n from 2 to 5000; R1 and R2 are side chains except —COOalkyl; and X1, X2 and X3 are independently O, S, or Se. Semiconductors and devices comprising the polymer are also provided.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: July 1, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Zhikuan Chen, Jun Li, Beng Ong, Samarendra P. Singh, Hoi Kai Ivy Wong, Kok Haw Ong
  • Patent number: 8765969
    Abstract: The invention provides compounds, compositions, methods, substrates, and kits useful for analyzing the metabolic activity in cells, tissue, and animals and for screening test compounds for their effect on cytochrome P450 activity. In particular, a one-step and two-step methods using luminogenic molecules, e.g. luciferins or coelenterazines, that are cytochrome P450 substrates and that are also bioluminescent enzyme, e.g., luciferase, pro-substrates are provided. The present method further provides a method for stabilizing and prolonging the luminescent signal in a luciferase-based assay using luciferase stabilizing agents such as reversible luciferase inhibitors.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: July 1, 2014
    Assignee: Promega Corporation
    Inventors: James J. Cali, Dieter Klaubert, William Daily, Samuel K. Ho, Susan Frackman, Erika Hawkins, Keith V. Wood
  • Patent number: 8765970
    Abstract: The present invention relates to a catalytic process for preparing 3-triazolyl sulphoxide derivatives in enantiomerically pure or enantiomerically enriched form.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: July 1, 2014
    Assignee: Bayer CropScience AG
    Inventors: Stefan Antons, Norbert Lui, Wahed Ahmed Moradi
  • Patent number: 8765971
    Abstract: The present invention relates to a novel process for preparing 5-fluoro-1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carbonyl chlorides, a useful intermediate in the manufacture of fungicides.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: July 1, 2014
    Assignee: Bayer CropScience AG
    Inventors: Sergii Pazenok, Norbert Lui, Marc Kosten, Guenter Bartels
  • Patent number: 8765972
    Abstract: There are provided substituted 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide derivatives (I) which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: July 1, 2014
    Assignee: Nerviano Medical Sciences S.r.l.
    Inventors: Gianluca Mariano Enrico Papeo, Alina Anatolievna Busel, Elena Casale, Alexander Khvat, Mikhail Yurievitch Krasavin, Paolo Orsini, Helena Posteri, Alessandra Scolaro
  • Patent number: 8765973
    Abstract: The invention is directed to compounds according to formula (I): where R1 is L1C(O)OT or L1C(O)OL2C(O)OT; R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R1; n is an integer from 0 to 5; each R3 is independently halogen or R2; R4 and R5 are independently H, halogen, CN or CF3; L1 and L2 are each independently a bond, a substituted or unsubstituted C1-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene; and T is H, a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, nitrophenol, or cyclopropyl. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and to methods for providing anesthesia in mammals by administering such a pharmaceutical composition.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: July 1, 2014
    Assignee: The General Hospital Corporation
    Inventors: Douglas E. Raines, Joseph F. Cotten, Stuart A. Forman, Keith W. Miller, Syed S. Husain, Gregory D. Cuny